Back to Search
Start Over
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
- Source :
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8042-8042, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 164014923
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.16_suppl.8042